 |
 |
 |
 |
 |
 |
 |
|
|||||||
|
Select Publications
Stephenson AJ et al. Prostate cancer-specific mortality after radical prostatectomy in the prostate-specific antigen era. Genitourinary Cancers Symposium 2008;Abstract 9.
Horwitz EM et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26(15):2497-504. Abstract
D’Amico AV et al. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008;26(18):2979-83. Abstract
D’Amico AV et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 2008;299(3):289-95. Abstract
Roach M III et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 2008;26(4):585-91. Abstract
Alibhai SM et al. Impact of androgen deprivation therapy (ADT) on bone, cardiovascular, and endocrine outcomes: A propensity-matched analysis of 20,000 patients. Proc ASCO 2008;Abstract 5012.
Camara C et al. High prevalence of metabolic syndrome in patients under long-term hormonal therapy for prostate cancer. Preliminary report. Proc AUA 2008;Abstract 401.
Donovan MJ et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008;26(24):3923-9. Abstract
Donovan MJ et al. Androgen receptor levels in both needle biopsy and prostatectomy specimens are associated with overall survival in castration resistant disease. Genitourinary Cancers Symposium 2008;Abstract 18.
Figg WD et al. Randomized phase III trial of thalidomide (Th) or placebo (P) for non-metastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy. Proc ASCO 2008;Abstract 5016.
Flaig TW et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008;26(9):1532-6. Abstract
Dawson N et al. Impact of the specific endothelin A receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: Results of a phase II trial. Genitourinary Cancers Symposium 2008;Abstract 7.
Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-71. Abstract
Lu-Yao GL et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300(2):173-81. Abstract
| Table of Contents | Top of Page |
